AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Oculis Holding AG

Share Issue/Capital Change Apr 25, 2025

8640_rns_2025-04-25_2ccddae6-6eaa-49df-8193-cf2f42f55483.html

Share Issue/Capital Change

Open in Viewer

Opens in native device viewer

Disclosure 458076

Oculis Holding AG - Total number of voting rights and capital

Oculis Updates Share Capital

ZUG, Switzerland, April 25, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each with a nominal value of CHF 0.01. The issuance comprises 589,974 registered shares, reflecting the settlement of 310,941 shares issued in connection with the exercise of equity awards under the Company’s Stock Option and Incentive Plan Regulation and 279,033 shares issued through EBAC warrant exercises pursuant to the Company‘s Articles of Association, during the period from January 1, 2024, to December 31, 2024.

As a result, the total number of registered shares as set forth in the Company’s Articles of Association has increased to 54,533,674. This increase has been registered with the Zug Commercial Register.

For more information, please visit:

http://www.oculis.com

Oculis Contact:

Ms. Sylvia Cheung, CFO

[email protected]

Investor & Media Relations:

LifeSci Advisors

Corey Davis, Ph.D.

[email protected]

Talk to a Data Expert

Have a question? We'll get back to you promptly.